The 52 references in paper A. Smirnov V., K. Smirnov A., А. Смирнов В., К. Смирнов А. (2009) “ПРОРЕНИН И РЕНИН – НОВЫЕ МИШЕНИ ДЛЯ РЕНО- И КАРДИОПРОТЕКТИВНОЙ ТЕРАПИИ // PRORENIN AND RENIN – NEW TARGETS FOR RENO- AND CARDIOPROTECTIVE THERAPY” / spz:neicon:nefr:y:2009:i:1:p:15-20

1
Ruster C, Wolf G. Renin- angiotensin- aldosteron system and progression of renal disease. J Am Soc Nephrol 2006; 17:
(check this in PDF content)
2
85-2991 2. Danser AHJ. Local renin- angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003; 35: 759-768
(check this in PDF content)
3
Kats JP, Schalekamp MADH, Verdouw PD et al. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001; 60: 2311-2317
(check this in PDF content)
4
Border WA, Noble NA. Interaction of transforming growth factor- beta and angiotensin II in renal fibrosis. Hypertension 1998: 31: 181-188
(check this in PDF content)
5
Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-I and renal fibrosis. Contib Nephrol 2001; 135: 153-160
(check this in PDF content)
6
Tokuda K, Kai H, Kuwahara F et al. Pressure- independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499-503
(check this in PDF content)
7
Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-272
(check this in PDF content)
8
Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control proteinuria and angiotensin-converting enzyme inhibition: a patient- level meta-analysis. Ann Intern Med 2003; 139: 244-252
(check this in PDF content)
9
Devereux RB, Dahlof B, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Cireulation 2004; 110: 1456-1462
(check this in PDF content)
10
Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570­ 1580
(check this in PDF content)
11
Border WA, Noble NA. Maximizing hemodynamic- independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 2001; 21: 563-572
(check this in PDF content)
12
Kurtz A, Wagner C. Regulation of renin secretion by angiotensin II- AT, receptors. J Am Soc Nephrol 1999; 10 (Suppl. 11): S162-S168
(check this in PDF content)
13
Azizi M, Bissery A, Lamarie-Cliche M, Menard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 2004; 43: 785-790
(check this in PDF content)
14
Danser AHJ, Derkx FHM, Schalekamp MADH et al. Determination of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998; 16: 853-862
(check this in PDF content)
15
Luetscher JA, Kraemer FB, Wilson DM et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412­ 1417
(check this in PDF content)
16
Deinum J, Ronn B, Mathiesen E et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42: 1006-1010
(check this in PDF content)
17
Maru I, Ohta J, Murata K et al. Molecular cloning and identification of N-acyl-D-glucosamine 2-epimerase from porcine kidney as a renin- binding protein. J Biol Chem 1996; 271: 16294-16299
(check this in PDF content)
18
Kesteren CAM, Danser AHJ, Derkx FHM et al. Mannose 6-phosphate receptor- mediated internalization and activation of prorenin by cardiac cells. Hypertension 1997; 30: 1389-1396
(check this in PDF content)
19
Saris JJ, van den Eijnden MMED, Lamers JMJ et al. Prorenin- induced myocyte proliferation: no role for intracellular angiotensin II. Hypertension 2002; 39: 573-577
(check this in PDF content)
20
Nguyen G, Delarue F, Berron J et al. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator ingibitor-1 antigen. Kidney Int 1996; 50: 1897-1903
(check this in PDF content)
21
Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427
(check this in PDF content)
22
Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforming growth factor-l1 and matrix proteins through receptor- mediated, angiotensin II- independent mechanisms. Kidney Int 2006; 69: 105-113
(check this in PDF content)
23
Saris JJ, Hoen PAC, Garrelds IM et al. Prorenin induces intracellular signaling in cardiomyocytes indepently of angiotensin II. Hypertension 2006; 48: 564-571
(check this in PDF content)
24
Burridge K, Wennerberg K. Rho and Rac take center stage Cell 2004; 116: 167-179
(check this in PDF content)
25
Huang X Noble NA, Zhang J et al. Renin-stimulated TGF-I1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007; 72: 45-52
(check this in PDF content)
26
Danser AHJ, Batenburg WW, van Esch JHM. Prorenin and the (pro)renin receptor-an update. Nephrol Dial Transplant 2007; 22: 1288-1292
(check this in PDF content)
27
Ichihara A, Hayashi M, Kaneshiro J et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135
(check this in PDF content)
28
Price DA, Porter ZE, Gordon M et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-239
(check this in PDF content)
29
Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blochers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67: 799-812
(check this in PDF content)
30
Azizi M, Menard J. Combined blockade of the renin- angiotensin system with angiotensin- converting enzyme inhibitors and angiotensin II type I receptor antagonists. Circulation 2004; 109: 2492-2499
(check this in PDF content)
31
Mc Murray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin - converting- enzyme inhibitors: the CHARM- Added trial. Lancet 2003; 362: 767- 771
(check this in PDF content)
32
Ruilope LM, Aldigier JC, Ponticelli C et al. Safety of the combination of valsartan and benasepril in patients with chronic renal disease: European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000; 18: 89-95
(check this in PDF content)
33
Krebs C, Hamming I, Sadaghiani S et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007; 72: 725- 730
(check this in PDF content)
34
Steinmetz OM, Sadaghiani S, Panzer U et al. Antihypertensive therapy induces compartment- specific chemokine expression and a Th 1 immune response in the clipped kidney of Goldblat hypertensive rats. Am J Physiol Renal Physiol 2007; 292: F876- F887
(check this in PDF content)
35
Hamming I, Navis G, Kocks MJ, van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006; 209: 129- 139
(check this in PDF content)
36
Dancer JAH, van Kats JP, Admiraal PJJ et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24: 37- 48
(check this in PDF content)
37
Segall L, Covic A, Goldsmith DJH. Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol Dial Transplant 2007; 22: 2435- 2439
(check this in PDF content)
38
Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta- analysis. Lancet 2005; 366: 1545-1553
(check this in PDF content)
39
Staessen JA, Li Y Richart T Oral renin inhibitors. Lancet 2006; 368: 1449- 1456
(check this in PDF content)
40
Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002; 39: e1- e8
(check this in PDF content)
41
O’Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin- converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49 276- 284
(check this in PDF content)
42
Mitchell J, Oh B, Herron J et al. Once-daily aliskiren provides effective, smoth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006; 8 [5 Suppl. A]: A93 (P-209)
(check this in PDF content)
43
Feldman DL, Persohn E, Schutz H et al. Renal localization of the renin inhibitor aliskiren. J Clin Hypertens 2006; 8 [ Suppl. A]: A80
(check this in PDF content)
44
Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose- dependent antihypertensive efficacy and placebo- like tolerability in hypertensive patients. Circulation 2005; 111: 1012- 1018
(check this in PDF content)
45
Uresin X Taylor A, Kilo C et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens 2006; 24 [Suppl. 4]: S82
(check this in PDF content)
46
Villamil A, Chrysant S, Calhoun D et al. The novel oral renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazide. J Clin Hypertens 2006; 8 [Suppl. A]: A101
(check this in PDF content)
47
Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11­ 20
(check this in PDF content)
48
Bomback AS, Klemmer PhJ. The incidence and implications of aldosterone breakthrough. Nature Clinical Practice Nephrology 2007; 3: 486-491
(check this in PDF content)
49
Vecchio LD, Procacio M, Vigano S, Cusi D. Mechanism of Disease: the role of aldosterone in Kidney damage and clinical benefits of its blockade. Nature Clinical Practice Nephrology 2007; 3 : 42- 49
(check this in PDF content)
50
Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci 2006; 100: 9­ 16
(check this in PDF content)
51
Bianchi S, Bigazzi R, Campese VM. Long- term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116- 2123
(check this in PDF content)
52
Shafig MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008; 121:265-271 Поступила в редакцию 02.12.2008 г. Принята в печать 10.02.2009 г.
(check this in PDF content)